Use of medicines and other products for therapeutic purposes among children in Brazil

Tatiane da Silva Dal Pizzol¹, Noemia Urruth Leão Tavares², Andréa Dâmaso Bertoldi³, Marení Rocha Farias⁴, Paulo Sergio Dourado Arrais¹, Luiz Roberto Ramos⁵, Maria Auxiliadora Oliveira⁶, Vera Lucia Luiza⁷, Sotero Serrate Mengue⁸

¹ Departamento de Produção e Controle de Medicamentos. Faculdade de Farmácia. Universidade Federal do Rio Grande do Sul. Porto Alegre, RS, Brasil
² Departamento de Farmácia. Faculdade de Ciências da Saúde. Universidade de Brasília. Brasília, DF, Brasil
³ Departamento de Medicina Social. Faculdade de Medicina. Universidade Federal de Pelotas. Pelotas, RS, Brasil
⁴ Departamento de Ciências Farmacêuticas. Centro de Ciências da Saúde. Universidade Federal de Santa Catarina. Florianópolis, SC, Brasil
⁵ Departamento de Farmácia. Faculdade de Farmácia, Odontologia e Enfermagem. Universidade Federal do Ceará. Fortaleza, CE, Brasil
⁶ Departamento de Medicina Preventiva. Escola Paulista de Medicina. Universidade Federal de São Paulo. São Paulo, SP, Brasil
⁷ Departamento de Política de Medicamentos e Assistência Farmacêutica - Escola Nacional de Saúde Pública Sérgio Arouca. Fundação Oswaldo Cruz. Rio de Janeiro, RJ, Brasil
⁸ Programa de Pós-Graduação em Epidemiologia. Universidade Federal do Rio Grande do Sul. Porto Alegre, RS, Brasil

ABSTRACT

OBJECTIVE: To assess the prevalence of the use of medicines and other products for therapeutic purposes in the Brazilian pediatric population and test whether demographic, socioeconomic and health factors are associated with use.

METHODS: A cross-sectional population-based study (National Survey on Access, Use and Promotion of Rational Use of Medicines – PNAUM), including 7,528 children aged 12 or younger, living in urban areas in Brazil. Medicine use to treat chronic or acute diseases was reported by the primary caregiver present at the household interview. Associations between independent variables and medicine use were investigated by Poisson regression.

RESULTS: The overall prevalence of medicine use was 30.7% (95%CI 28.3–33.1). The prevalence of medicine use for chronic diseases was 5.6% (95%CI 4.7–6.7) and for acute conditions, 27.1% (95%CI 24.8–29.4). The factors significantly associated with overall use were five years old or under, living in the Northeast region, having health insurance and using health services in the last 12 months (emergency visits and hospitalizations). The following were associated with drug use for chronic diseases: age ≥ 2 years, Southeast and South regions, and use of health services. For drug use in treating acute conditions, the following associated factors were identified: ≤ 5 years, North, Northeast or Midwest regions, health insurance, and one or more emergency visits. The most commonly used drugs among children under two years of age were paracetamol, ascorbic acid, and dipyrone; for children aged two years or over they were dipyrone, paracetamol, and amoxicillin.

CONCLUSIONS: The use of medicine by children is considerable, especially in treating acute medical conditions. Children using drugs for chronic diseases have a different demographic profile from those using drugs for acute conditions in relation to gender, age, and geographic region.

DESCRIPTORS: Child. Child, Preschool. Drug Utilization. Socioeconomic Factors. Health Surveys.
INTRODUCTION

Drug use in children differs from drug use in adults for various reasons, especially lower prevalence of chronic diseases and higher degree of uncertainty in prescription and use. The uncertainty regarding the effectiveness and safety of medicines available for this population subgroup contributes to children being considered a risk group. Most drugs used in children have only been tested in adults, and it is observed a lack of products available in age-appropriate pharmaceutical formulations and dosage forms, as well as of studies on long-term effectiveness and safety.

In 2007, the World Health Organization launched the campaign “Make Medicines Child Size” and published the First List of Essential Medicines for Children, aiming to raise awareness and speed up action to improve the availability of and access to medicines that are safe and suitable for children. Regulatory measures and measures to foster the research, development, and registration of drugs for use in children have occurred in the United States (US) and the European Union. Organizations like UNITAID, Drugs for Neglected Diseases initiative (DNDi) and Medicines Patent Pool (MPP) have stimulated the development and provision of appropriate medicines for children, such as for HIV and neglected diseases.

These initiatives highlight the need to develop better medicines for children, an area that is considered neglected by various international organizations. In this regard, information on the prevalence of drug use, user characteristics and medicines used by the pediatric population are important to evaluate the appropriateness of use and estimate therapeutic needs, to improve pediatric therapeutics.

In this context, community-based epidemiological studies offer a unique opportunity to profile drug use. Such studies provide more accurate estimates and enable a greater generalization of findings compared to studies based on samples of health service users, disease-specific carriers, or on data collected for other purposes (prescriptions or dispensing data, for example).

In Brazil, no study with a representative sample of the country has been carried out, and population-based studies have been limited to samples of children living in municipalities in the South, Southeast, and Northeast Regions. In these studies, prevalence of use of at least one medicine ranged around 50.0%, with variations according to the age group investigated.

The aim of this study was to estimate the prevalence of the use of drugs and other products for therapeutic purposes in the Brazilian pediatric population and test whether demographic, socioeconomic and health factors are associated with use.

METHODS

The data in this analysis are part of the National Survey on Access, Use and Promotion of Rational Use of Medicines (PNAUM), a cross-sectional population-based study. The study’s population was composed of individuals aged 12 or younger living in permanent private households in urban areas within the five Brazilian regions. Specific questionnaires were answered by the primary caregiver present at the residence at the time of the interview.

The sampling plan was complex and resulted in a representative sample of the Brazilian population residing in urban areas. The composition of the sample, sampling procedures and other methodological details of PNAUM are available in a previous publication.

The use of drugs to treat chronic diseases was investigated for respiratory diseases, diabetes, and other health conditions lasting six months or longer. Specific questions...
were formulated for chronic respiratory diseases and diabetes, since they are diseases with high prevalence among children or that require complex administration of medicines. Caregivers were asked whether the child had a medical diagnosis and indication for the use any kind of drug to treat the related chronic disease and whether such medicines was being used.

For acute conditions (occasional health problems), specific questions were asked ("In the past 15 days, did <<child’s name>> use any medicine for infection/sleeping or nervous symptoms/stomach or bowel problems/fever/pain/cold or flu/diarrhea and vomiting?"). The use of vitamins was also investigated with the question "In the last 15 days, did <<child’s name>> use any vitamin, mineral supplement, appetite stimulant or tonic?" At the end of this set of questions, the respondent was asked about the use of drugs in the previous 15 days for any other health reasons. They were asked to provide, whenever possible, the packages or prescriptions of used medicines.

Outcomes to investigate prevalence in the pediatric sample were defined as:
1) prevalence of overall drug use (use of at least one drug, regardless of reason for use);
2) prevalence of drug use for chronic diseases (use of at least one drug to treat chronic disease);
3) prevalence of drug use for acute diseases or conditions (use of at least one drug to treat acute disease or health event). The outcome variables were categorized as yes/no. Prevalence calculation included herbal medicines and other products for therapeutic purposes mentioned by respondents (dietary supplements, foods, plants, and homeopathic products).

The following demographic and socioeconomic characteristics were analyzed: gender (female; male), age (< 2 years; 2-5 years; 6-12 years), skin color (white; non-white), economic classification according to the Economic Classification Criterion developed by the Brazilian Association of Survey Companies (CCEB 2013/ABEP) (A/B, C, D/E) and Brazilian region (North, Northeast, Southeast, South, Midwest). Medical variables were: health insurance (yes; no); number of emergency visits in the last 12 months (none; one; two or more); and number of hospitalizations in the last 12 months (none; one; two or more).

The age group investigated was based on the classification adopted by the Food and Drug Administration (FDA) for clinical investigation of medicines for pediatrics, more commonly used in previous studies, to facilitate comparison of results. We chose to analyze children aged 12 and under, as this is an age group in which drug use is still determined and directly supervised by parents or caregivers.

Based on the names of the products or medicines mentioned by respondents, the drugs were identified in The Brazilian Health Regulatory Agency (ANVISA) drug lists and classified according to the pharmacological agent(s) present in their composition. Drugs used in combination (containing two or more pharmacological agents in their composition) were considered just once.

In calculating prevalence of drug use, the total number of children in the weighted sample was used as the denominator, with 95% confidence intervals (95%CI). Likewise, estimates of prevalence of drug use with frequency equal to or above 0.5% also used as the denominator the total number of children present in the weighted sample, stratified by age (< 2 years; 2-5 years; 6-12 years). For the description of the most commonly used drugs, the percentage denominator was the total amount of drugs in each age group.

Pearson's Chi-squared test was used for the bivariate comparison of percentages, considering p < 0.05 values as significant.

Associations between independent variables and outcomes were estimated by prevalence ratio (PR), with 95%CI. Poisson regression models were developed to estimate crude PR and PR adjusted for independent variables. In the first stage, independent variables...
were analyzed individually. Variables showing statistical significance, defined as $p < 0.20$ in univariate analyses were selected for the second stage, in which all variables were introduced in the multiple model. At this stage, variables showing $p > 0.05$ were removed from the model one by one, with “backward” selection of variables. Statistical significance of the prevalence ratios obtained in the Poisson regression models was assessed by the Wald test.

Data were stored in SPSS software for Windows version 18.0 (SPSS Inc., Chicago, IL, USA). Descriptive analyses were executed in SPSS and the Poisson regression models were executed in Stata software version 12.0 (Stata Corp LP, College Station, TX, USA), using the appropriate set of `svy` commands for the analysis of complex samples and ensuring the necessary weighting, considering the sample design.

The project was approved by the Brazilian National Commission for Research Ethics (CONEP – Opinion 398,131, September 16, 2013). Participants were only interviewed following permission by means of an informed consent signed by the researcher and the participant.

RESULTS

The children’s characteristics are shown in Table 1. The study population is comparable to that of the 2010 Census in relation to gender (50.9% boys and 49.1% girls), age (< 2 years: 13.9%; 2-5 years: 29.0%; 6-12 years: 57.1%) and Brazilian region (North: 10.9%; Northeast: 30.7%; Southeast: 37.9%; South: 12.9%; and Midwest: 6.7%)$^c$.

The questionnaires were answered by the child’s mother in 76.1% of cases, followed by grandparent (9.6%) and father (8.6%).

Prevalence of chronic diseases was 9.9% (95%CI 8.6–11.3). Diabetes was reported by 0.4% of the sample (95%CI 0.2–0.8%) and chronic lung diseases by 5.2% (95%CI 4.3–6.4). Prevalence of acute conditions treated in the 15 days prior to the interview was 27.4% (95%CI 25.2–29.8). The most common were fever (8.4%; 95%CI 7.4–9.5), cold or flu (7.3%; 95%CI 6.2–8.5), pain (5.8%; 95%CI 4.8–7.0%) and infection (4.6%; 95%CI 3.8–5.5). The use of vitamins or mineral supplements was reported by 6.1% (95%CI 5.3–7.1).

Table 1 shows the prevalence of overall use of drugs and other products for therapeutic purposes (30.7%). Use was highest among children aged five or under, resident in the Northeast Region, with health insurance and who had used health services in the previous 12 months (one or more emergency visits and one or more hospitalizations). In the final model, these factors remained positively associated with the outcome, with statistical significance.

Table 2 shows the prevalence of drugs used to treat chronic (5.6%) and acute diseases (27.1%). Two years old or over, resident in the Southeast or South Regions, one or more emergency visits, and one or more hospitalizations remained positively associated with the use of medicines for chronic diseases. The positive association between health insurance and the outcome failed to show any statistical significance when adjusted for other variables.

The following factors were associated with the use of medicines to treat acute conditions in the crude analysis: five years old or younger, resident in the North, Northeast, and Midwest Regions, health insurance, and use of health services. In the multivariate analysis, these factors remained positively associated with the outcome and statistically significant, except for the number of hospitalizations. Belonging to economic classes A/B was negatively associated with the outcome, but not sustained after adjustment for covariates.

---

$^c$ Instituto Brasileiro de Geografia e Estatística. Censo demográfico 2010: características da população e dos domicílios: resultado do universo. Rio de Janeiro (RJ): IBGE; 2011 [cited 2016 Feb 29]. Available from: http://www.ibge.gov.br/home/estatistica/populacao/censo2010/caracteristicas_da_populacao/default_caracteristicas_da_populacao.shtm
Table 1. Sample characteristics and overall prevalence of medicine use, according to demographic, socioeconomic and medical variables\textsuperscript{a}. (N = 7,528)

| Variable                      | Sample | Overall medicine use |
|-------------------------------|--------|----------------------|
|                               | %      | Prevalence           | 95%CI | \(p\)   | \(PR_{\text{crude}}\) | 95%CI | \(PR_{\text{adjusted}}\) | 95%CI |
| Overall                       | 100    | 30.7                 | 28.3–33.1 | -       | -       | -       | -       |
| Gender                        |        |                      |       |         |         |         |         |
| Female                        | 50.3   | 29.5                 | 26.6–32.5 | 1       | -       | 1       | -       |
| Male                          | 49.7   | 31.9                 | 28.6–35.3 | 1.08    | 0.94–1.24 | 1.08    | 0.94–1.24 |
| Age (years)                   |        |                      |       |         |         |         |         |
| < 2                           | 13.5   | 48.0                 | 44.8–51.2 | 2.01    | 1.77–2.29 | 1.78    | 1.58–2.00 |
| 2-5                           | 26.9   | 37.1                 | 34.4–39.9 | 1.56    | 1.36–1.78 | 1.33    | 1.17–1.52 |
| 6-12                          | 59.6   | 23.8                 | 20.9–27.0 | 1       | -       | 1       | -       |
| Skin color                    |        |                      |       | 0.95    |         |         |         |
| White                         | 46.7   | 30.8                 | 27.9–33.8 | 1       | -       | 1       | -       |
| Non-white                     | 53.3   | 30.9                 | 28.0–33.9 | 1.00    | 0.90–1.12 | 1.00    | 0.90–1.12 |
| Economic classification\textsuperscript{d} |        |                      |       | 0.2     |         |         |         |
| A/B                           | 16.8   | 27.0                 | 22.9–31.4 | 1       | -       | 1       | -       |
| C                             | 56.2   | 31.5                 | 28.7–34.5 | 1.17    | 0.99–1.38 | 1.17    | 0.99–1.38 |
| D/E                           | 27.0   | 31.1                 | 27.3–35.2 | 1.15    | 0.96–1.39 | 1.09    | 0.91–1.31 |
| Brazilian Region              |        |                      |       | < 0.0001 |         |         |         |
| North                         | 9.9    | 32.5                 | 25.5–40.3 | 1.24    | 0.94–1.63 | 1.22    | 0.97–1.53 |
| Northeast                     | 26.7   | 38.4                 | 34.9–42.0 | 1.47    | 1.23–1.74 | 1.34    | 1.14–1.57 |
| Southeast                     | 41.2   | 26.9                 | 22.8–31.5 | 1.03    | 0.83–1.28 | 0.99    | 0.81–1.20 |
| South                         | 13.8   | 26.2                 | 22.5–30.2 | 1       | -       | 1       | -       |
| Midwest                       | 8.4    | 29.7                 | 25.7–34.0 | 1.13    | 0.92–1.39 | 1.04    | 0.86–1.26 |
| Health Insurance              |        |                      |       | < 0.0001 |         |         |         |
| Yes                           | 19.3   | 37.9                 | 33.0–43.0 | 1.31    | 1.13–1.51 | 1.28    | 1.11–1.47 |
| No                            | 80.7   | 28.9                 | 26.5–31.05 | 1       | -       | 1       | -       |
| No. of emergency visits\textsuperscript{e} |        |                      |       | < 0.0001 |         |         |         |
| None                          | 84.1   | 24.8                 | 22.7–27.0 | 1       | -       | 1       | -       |
| Two                           | 9.5    | 51.5                 | 44.3–58.7 | 2.08    | 1.76–2.45 | 1.79    | 1.52–2.11 |
| Two or more                   | 6.4    | 75.9                 | 70.6–80.4 | 3.06    | 2.75–3.41 | 2.48    | 2.18–2.81 |
| No. of hospitalizations\textsuperscript{e} |        |                      |       | < 0.0001 |         |         |         |
| None                          | 95.1   | 29.0                 | 26.7–31.5 | 1       | -       | 1       | -       |
| One                           | 4.0    | 59.8                 | 50.6–68.3 | 2.06    | 1.75–2.43 | 1.31    | 1.10–1.56 |
| Two or more                   | 0.9    | 85.4                 | 74.6–92.1 | 2.94    | 2.58–3.34 | 1.37    | 1.19–1.58 |

\textsuperscript{a} Percentages weighted by the sampling weights.
\textsuperscript{b} Pearson’s Chi-Squared test.
\textsuperscript{c} Poisson Regression.
\textsuperscript{d} 2013 Brazilian Economic Classification according to ABEP.
\textsuperscript{e} Regarding the 12 month-period prior to the interview.
Table 2. Prevalence of medicine use for chronic diseases and acute conditions, according to demographic, socioeconomic and medical variables. (N = 7,528)

| Variable                      | Medicine use for chronic diseases | Medicine use for acute conditions |
|-------------------------------|-----------------------------------|-----------------------------------|
|                               | Prevalence (95%CI) | PR<sub>crude</sub> (95%CI)<sup>a</sup> | PR<sub>adjusted</sub> (95%CI)<sup>a</sup> | Prevalence (95%CI) | PR<sub>crude</sub> (95%CI)<sup>a</sup> | PR<sub>adjusted</sub> (95%CI)<sup>a</sup> |
| Overall                       | 5.6 (4.7–6.7)      | 27.1 (24.8–29.4)                  |                                            |                        |                                            |                                            |
| Gender                        | 0.174              | 0.302                             |                                            |                        |                                            |                                            |
| Female                        | 4.9 (3.7–6.4)      | 1.32 (0.88–1.98)                  | 1.33 (0.91–1.94)                          | 28.0 (25.0–31.3)      | 1.07 (0.94–1.23)                          | 1.07 (0.94–1.23)                          |
| Male                          | 6.4 (4.9–8.3)      | 26.1 (23.5–28.9)                  |                                            |                        |                                            |                                            |
| Age (years)                   | 0.003              | < 0.001                           |                                            |                        |                                            |                                            |
| < 2                           | 3.7 (2.8–4.8)      | 1.32 (0.88–1.98)                  | 1.33 (0.91–1.94)                          | 26.1 (23.5–28.9)      | 1.07 (0.94–1.23)                          | 1.07 (0.94–1.23)                          |
| 2-5                           | 7.5 (6.0–9.3)      | 2.05 (1.51–2.80)                  | 2.14 (1.56–2.94)                          | 32.9 (30.0–35.8)      | 1.64 (1.43–1.89)                          | 1.44 (1.25–1.66)                          |
| 6-12                          | 5.2 (4.1–6.7)      | 1.43 (1.02–2.01)                  | 1.88 (1.35–2.61)                          | 20.0 (17.4–22.9)      | 1.07 (0.94–1.23)                          | 1.07 (0.94–1.23)                          |
| Skin color                    | 0.104              | 0.779                             |                                            |                        |                                            |                                            |
| White                         | 6.4 (5.1–8.1)      | 1.30 (0.95–1.78)                  | 1.10 (0.76–1.60)                          | 27.0 (24.2–29.9)      | 0.98 (0.87–1.11)                          | 0.98 (0.87–1.11)                          |
| Non-white                     | 5.0 (3.9–6.3)      | 27.5 (24.7–30.4)                  |                                            |                        |                                            |                                            |
| Economic classification<sup>d</sup> | 0.537               | 0.097                             |                                            |                        |                                            |                                            |
| A/B                           | 5.6 (3.7–8.4)      | 1.18 (0.68–2.06)                  | 1.18 (0.68–2.06)                          | 22.7 (18.9–27.0)      | 0.80 (0.65–0.98)                          | 0.87 (0.70–1.08)                          |
| C                             | 6.0 (4.8–7.5)      | 1.26 (0.81–1.97)                  | 1.26 (0.81–1.97)                          | 27.6 (24.6–30.6)      | 0.97 (0.83–1.13)                          | 1.05 (0.91–1.20)                          |
| D/E                           | 4.8 (3.3–6.9)      | 28.5 (24.8–32.5)                  |                                            |                        |                                            |                                            |
| Brazilian Region              | < 0.001            | < 0.001                           |                                            |                        |                                            |                                            |
| North                         | 2.6 (1.6–4.0)      | 1.53 (1.14–2.06)                  | 1.52 (1.19–1.96)                          |                        |                                            |                                            |
| Northeast                     | 4.3 (3.1–6.0)      | 1.76 (1.43–2.17)                  | 1.61 (1.33–1.95)                          |                        |                                            |                                            |
| Southeast                     | 6.8 (5.0–9.2)      | 1.13 (0.87–1.46)                  | 1.10 (0.88–1.38)                          |                        |                                            |                                            |
| South                         | 7.7 (6.3–9.5)      | 20.2 (16.7–24.2)                  |                                            |                        |                                            |                                            |
| Midwest                       | 4.4 (2.6–6.0)      | 27.5 (23.5–32.0)                  |                                            |                        |                                            |                                            |
| Health Insurance              | 0.021              | 0.007                             |                                            |                        |                                            |                                            |
| Yes                           | 8.4 (5.6–12.2)     | 32.2 (27.9–36.9)                  |                                            |                        |                                            |                                            |
| No                            | 5.0 (4.1–6.0)      | 25.8 (23.4–28.3)                  |                                            |                        |                                            |                                            |
| No. of emergency visits<sup>e</sup> | < 0.001            | < 0.001                           |                                            |                        |                                            |                                            |
| None                          | 4.0 (3.3–5.0)      | 22.2 (20.1–24.3)                  |                                            |                        |                                            |                                            |
| Two                           | 7.5 (4.9–11.3)     | 45.2 (38.5–52.1)                  |                                            |                        |                                            |                                            |
| Two or more                   | 22.2 (16.2–29.7)   | 64.2 (58.0–70.1)                  |                                            |                        |                                            |                                            |
| No. of hospitalizations<sup>e</sup> | < 0.001            | < 0.001                           |                                            |                        |                                            |                                            |
| None                          | 4.7 (3.8–5.7)      | 26.1 (23.9–28.5)                  |                                            |                        |                                            |                                            |
| One                           | 17.8 (11.3–26.9)   | 46.7 (38.0–55.7)                  |                                            |                        |                                            |                                            |
| Two or more                   | 44.3 (27.8–62.1)   | 55.9 (37.8–72.6)                  |                                            |                        |                                            |                                            |

<sup>a</sup> Percentages weighted by the sampling weights.
<sup>b</sup> Pearson's Chi-Squared test.
<sup>c</sup> Poisson Regression.
<sup>d</sup> 2013 Brazilian Economic Classification according to ABEP.
<sup>e</sup> Regarding the 12 month-period prior to the interview.
Of the total number of products or drugs reported (5,185), 91.4% (95%CI 89.9–92.6) corresponded to medicines, 1.7% (95%CI 1.3–2.4) to dietary supplements (low-dose vitamin combinations), 1.2% (95%CI 0.9–1.7) to herbal medicines, 1.1% (95%CI 0.7–1.9) to plants or teas, 0.5% (95%CI 0.3–0.8) to food (honey compounds), and 0.1% (95%CI 0.0–0.7) to homeopathic medicines. The name of 3.9% (95%CI 3.0–5.1) of the products was not identified.

Table 3 shows the prevalence of medicines most used by Brazilian children (equal to or above 0.5%). Considering the total sample, the highest prevalence in drug use was observed for dipyrone (5.1%; 95%CI 4.3–6.1), paracetamol (4.3%; 95%CI 3.6–5.1), and amoxicillin (2.7; 95%CI 2.2–3.4).

Tables 4 and 5 show, for each age group, the drugs reported in treating chronic and acute diseases, respectively. Prominent among the total number of drugs to treat chronic diseases were those acting on the respiratory system (salbutamol, dexchlorpheniramine, fluticasone, and phenoterol), in all age groups (Table 4). Painkillers were the most cited drugs for treating acute conditions (Table 5).

### Table 3. Prevalence of most often used medicines (prevalence of use ≥ 0.5%) by children, by age group*. (N = 7,528)

| Drugb | 2-5 years (n = 3,671) | 6-12 years (n = 1,555) | Total (n = 7,528) |
|-------|----------------------|------------------------|------------------|
|       | Prevalence 95%CI     | Prevalence 95%CI       | Prevalence 95%CI |
| Dypirone | 5.7 4.5–7.2          | 6.2 4.9–7.7            | 5.1 4.3–6.1      |
| Paracetamol | 10.1 8.6–11.8       | 5.9 4.6–7.5            | 4.3 3.6–5.1      |
| Amoxicillin | 3.4 2.6–4.6         | 4.0 3.2–5.0            | 2.7 2.2–3.4      |
| Ibuprofen  | 3.9 3.0–5.0          | 3.3 2.5–4.5            | 2.4 1.9–3.1      |
| Ascorbic acid  | 6.9 5.5–8.6         | 1.9 1.3–2.9            | 1.6 1.3–2.0      |
| Dexchlorpheniramine | 1.5 1.0–2.2       | 1.7 1.2–2.4            | 1.6 1.2–2.2      |
| Ambroxol     | 1.3 0.8–2.0          | 1.3 0.8–2.3            | 1.0 0.7–1.4      |
| Prednisolone | 1.7 1.1–2.8         | 1.6 1.2–2.2            | 1.0 0.7–1.4      |
| Ferrous sulphate  | 4.0 3.0–5.5        | 0.4 0.2–0.7            | 0.9 0.6–1.3      |
| Cholecalciferol; retinol  | 5.7 3.9–8.3       | 0.2 0.1–0.6            | 0.8 0.6–1.2      |
| Multivitamins | 4.0 3.0–5.3        | 0.4 0.2–0.6            | 0.7 0.5–0.9      |
| Dimethicone  | 3.7 2.8–5.1          | 0.6 0.2–1.8            | 0.7 0.5–1.1      |
| Loratadine  | 0.6 0.3–1.1          | 0.9 0.6–1.4            | 0.6 0.4–1.0      |
| Fluticasone  | 0 0.0–0.3            | 0.7 0.2–1.8            | 0.6 0.2–1.6      |
| Sulfamethoxazol; trimethoprim  | 0.9 0.6–1.4       | 1.0 0.7–1.5            | 0.5 0.3–0.7      |
| Salbutamol   | 0.7 0.4–1.4          | 0.9 0.6–1.3            | 0.5 0.3–0.8      |
| Nimesulide | 0.4 0.2–0.8          | 0.5 0.3–0.9            | 0.5 0.3–0.8      |
| Cephalexin  | 0.9 0.6–1.5          | 0.8 0.4–1.5            | 0.5 0.3–0.8      |
| Amoxicillin; potassium clavulanate  | 0.4 0.2–1.1       | 0.9 0.4–2.0            | 0.5 0.2–0.9      |
| Phenoterol   | 0.4 0.2–1.0          | 0.7 0.3–1.4            | 0.5 0.3–0.9      |

* Percentages weighted by the sampling weights.

b Excluding supplements, food, plants and herbal medicines.
Table 4. Most used medicines (frequency > 1.0%) for chronic diseases, by age group*.

| Medicine                        | < 2 years | Preschool age (2-5 years) | School age (6-12 years) |
|---------------------------------|-----------|---------------------------|-------------------------|
| (n = 119 medicines)             |           | (n = 295 medicines)       | (n = 115 medicines)     |
|                                 | %         | 95%CI                      | %                       | 95%CI                   |
| Salbutamol                      | 8.4 3.5–18.7 | Salbutamol 5.8 3.4–9.9     | Carbamazepine 9.1 3.8–20.4 |
| Prednisolone                    | 7.2 3.0–15.9 | Phenoterol 5.3 2.6–10.6    | Fluticasone 9.1 2.8–26.0 |
| Deschlorpheniramine             | 7.0 3.0–15.4 | Fluticasone 5.0 1.7–13.4   | Deschlorpheniramine 5.6 2.0–15.0 |
| Amoxicilin                      | 6.6 2.7–15.4 | Prednisolone 4.5 2.5–8.1   | Phenoterol 4.9 1.8–12.4 |
| Beclomethasone                  | 5.5 1.5–18.0 | Ipratropium 4.2 1.7–9.7    | Salbutamol 4.7 2.0–10.7 |
| Ferrous sulphate                | 4.1 1.2–13.0 | Phenobarbital 4.0 1.5–9.9  | Budesonide; formoterol 4.6 1.4–14.0 |
| Phenobarbital                   | 3.7 1.5–8.9 | Sodium chloride 3.7 0.9–13.9 | Ipratropium 3.6 0.9–12.5 |
| Bethametasone; Deschlorpheniramine | 3.2 1.1–9.0 | Beclomethasone 3.6 1.7–7.4 | Levothyroxine 3.1 0.7–12.8 |
| Loratadine                      | 3.1 0.7–12.7 | Risperidone 3.4 0.7–14.4   | Methylphenidate 3.0 0.6–12.8 |
| Sodium chloride                 | 2.6 0.9–7.9 | Desloratadine 3.4 0.7–14.3 | Loratadine 3.0 0.8–10.4 |
| Prednisone                      | 2.6 0.3–17.4 | Ketotifen 2.9 0.9–9.3      | Budesonide 3.0 1.0–8.2 |
| Bronopheniramine; Phenylephrine | 2.5 0.5–11.9 | Ascorbic acid 2.9 0.4–17.4 | Prednisolone 2.9 1.0–7.8 |
| Multivitamins                   | 2.4 0.3–16.0 | Vitamins B Complex* 2.9 0.4–17.4 | Tacrolimus 2.5 0.5–12.9 |
| Dexamethasone                   | 2.3 0.7–7.6 | Pericyazine 2.9 0.5–15.5   | Human insulin 2.5 0.3–16.6 |
| Domperidone                     | 2.2 0.7–6.8 | Deschlorpheniramine 2.3 1.1–5.0 | Methylprednisolon acetate 2.3 0.3–13.5 |
| Ketotifen                       | 2.2 0.3–14.1 | Carbamazepine 2.2 0.6–7.2  | Divalproex sodium 2.1 0.3–14.0 |
| Cromoglycate                    | 2.2 0.3–13.0 | Budesonide 2.1 0.9–4.6     | Oxcarbazepine 2.1 0.3–13.5 |
| Acebrophylline                  | 2.1 0.7–6.0 | Montelukast 2.0 0.8–4.9    | Topiramate 2.1 0.3–13.5 |
| Ambroxol                        | 1.9 0.4–9.3 | Betamethasone; Deschlorpheniramine 2.0 0.6–5.9 | Folic acid 1.7 0.4–7.8 |
| Folic acid                      | 1.9 0.3–12.9 | Amoxicilin 1.9 0.8–4.3     | Olopatadine 1.5 0.2–10.9 |
| Ibuprofen                       | 1.8 0.6–4.9 | Dihidroxizine 1.8 0.3–10.4 | Phenobarbital 1.4 0.2–7.8 |
| Thiaibendazol                   | 1.6 0.2–11.3 | Loratadine 1.7 0.6–4.4     | Calcitriol 1.2 0.2–8.7 |
| Phenoterol                      | 1.5 0.2–10.6 | Clobutinol; doxylamine 1.7 0.2–10.8 | Biperiden 1.2 0.2–8.3 |
| Desloratadine                   | 1.3 0.3–6.1 | Calcium; nicotinamide; panthenol; ascorbic acid 1.6 0.2–10.9 | Chlorpromazine 1.2 0.2–8.3 |
| Amoxicilin; potassium Clavulanate | 1.3 0.2–9.1 | Ibuprofen 1.4 0.5–4.2      | Dimethicone 1.2 0.2–8.3 |
| Ferripolmaltose                 | 1.2 0.2–6.1 | Acebrophylline 1.4 0.5–3.9 | Dipyra; scopolamine 1.2 0.2–8.3 |
| Beclomethasone; salbutamol      | 1.1 0.1–7.5 | Mometasone 1.3 0.5–3.4     | Haloperidol 1.2 0.2–8.3 |
| Budesonide                      | 1.1 0.2–6.8 |                      |                        |
| Cholecalcidol; retinol          | 1.1 0.2–6.8 | Sodium picosulfate 1.2 0.2–8.7 |
| Ranitidine                      | 1.1 0.2–6.8 |                      |                        |

* Excluding herbal medicines and other products for therapeutic purpose reported by respondents (dietary supplements, food, plants and homeopathic products).
* Biotin, cyanocobalamin, pyridoxine, thiamine, riboflavin, nicotinamide, panthenol and calcium pantothenate.
DISCUSSION

This is the first study of drug use in children with a representative sample of the Brazilian urban population, providing estimates of the prevalence of drug use based on the chronic or acute nature of the treated health problem. The profile of medicine users and the most frequently used pharmacological agents in each phase of childhood are also described in this study.

Prevalence of overall drug use was lower than that observed in studies involving drug use in the previous seven days by children under 12 living in the US (56.0%) and individuals aged zero to 17 in Germany (50.8%). However, it was similar to that observed in surveys based on two-week periods in Spain and Norway. In Spain, surveys with children aged zero to 15 carried out in 1993 and 2003 showed prevalence rates of 36.8% and 34.0%, respectively. In Norway, about 25.0% of children up to four years of age used medicines, decreasing to approximately 20.0% among older children. Compared to studies carried out in Brazil, prevalence was lower than that observed in Salvador, BA, Bagé, RS, and the Jequitinhonha Valley, MG.

The significant difference between prevalence of drug use to treat chronic diseases and acute conditions was expected, considering that this population group is characterized by predominantly healthy individuals. Although Cox et al. (2008) observed an increase in the prevalence of certain chronic diseases among American children aged five to 19, children are most commonly affected by acute medical conditions, directly influencing how drugs are used (continuous versus occasional use).

The lack of difference in prevalence of overall drug use or related to acute events between boys and girls is in accordance with recent studies. The decrease in the prevalence of overall drug use or related to acute conditions as age increases corroborates findings from studies that showed increased use among children under two years old, compared to older...
children\textsuperscript{4,12,15,16}. These findings indicate that the first 24 months of life, when children are more susceptible to diseases and receive more medical care, either elective or emergency, are followed by a period of low incidence of acute conditions, which lasts approximately until early adolescence. Menarche-related events entail the use of painkillers and contraceptives by adolescent girls, contributing to increased prevalence in this age group\textsuperscript{2}.

The data of this study show that the profile of drug use to treat acute or chronic health conditions differs according to region. The highest prevalence of use for chronic conditions was observed in the South and Southeast Regions, associated with the higher prevalence of chronic respiratory diseases in these regions (data not shown). The use of drugs for acute conditions, higher in the Northeast and North Regions, can be explained by the higher frequency of medicine use for diarrhea and other gastrointestinal disorders, and the higher percentage of self-medication in these regions, according to PNAUM data not shown.

An overall positive association was found between use of health services and use of medicines, in line with data from the 2003 Spanish survey\textsuperscript{4}. Contact with health care services provides greater chances of children receiving medical prescriptions, which may lead to the routine use of prescription drugs or new posterior use.

Medicines to control pain and fever are among the most used, according to previous studies\textsuperscript{4,8,19,25}. Dipyridamole is the most used analgesic and antipyretic, followed by paracetamol and ibuprofen. This pattern differs from that observed in studies carried out in countries where the use of dipyridamole has been banned or restricted, as in the US, where ibuprofen stands out as the second most used painkiller\textsuperscript{25}. Amoxicillin was the most used antimicrobial in all age groups, with higher prevalence among children aged two to five (4.0%) and lower prevalence among children aged six to 12 (2.0%). In the US, amoxicillin also ranked as the most widely used antimicrobial, with higher prevalence among children under two years of age (5.1%) and lower prevalence in the six to 11 age group (1.5%)\textsuperscript{25}. With the exception of dipyridamole, whose safety controversies have persisted for years, the other drugs mentioned are considered effective and safe, with good evidence for pediatric use\textsuperscript{21}.

Another fact that draws attention relates to the use of vitamins, alone or in combination. The use of ascorbic acid alone was superior to the use of multivitamins in all age groups investigated, in contrast to the findings of a US study, in which multivitamins were mentioned more often\textsuperscript{25} (2009). In Salvador, vitamin C was used more often than multivitamins, although the difference observed in prevalence of use was smaller\textsuperscript{24}.

Prominent among the 10 most mentioned drugs for use in chronic diseases are those indicated for respiratory diseases such as asthma and rhinitis, followed by those with therapeutic use in epilepsy. Among children below two years old it is observed use of various drugs without FDA approval for this age group and no indication in the standard package inserts approved by ANVISA\textsuperscript{4}. Among the most frequently cited drugs with restrictions for use in this age group are salbutamol, dexchlorpheniramine (alone or combined with betamethasone), loratadine, and brompheniramine + phenylephrine. It should be noted that, in some cases, drugs not approved by the FDA are indicated in Brazilian standard package inserts, as is the case of betamethasone and ambroxol\textsuperscript{e}. If, on the one hand, the use of non-approved drugs may represent a potentially inappropriate administration of drugs whose efficacy and safety have not been established, on the other it may reflect the lack of therapeutic options to treat health conditions prevalent in children, such as asthma, rhinitis, and acute or chronic coughing, among others\textsuperscript{5}.

Among children under two years of age, one of the most used drugs to treat chronic diseases was amoxicillin. This can be explained by recurrent respiratory infections in this age group, identified as chronic by parents or caregivers for occurring with high frequency in short periods of time. This finding should be considered in the context of the increase in antimicrobial resistance rates reported worldwide and in Brazil\textsuperscript{11,22}.  

\textsuperscript{4} Ministério da Saúde, Agência Nacional de Vigilância Sanitária. Bulário eletrônico. Brasília (DF); s.d [cited 2016 Feb 20]. Available from: http://www.anvisa.gov.br/datavisa/fila_bula/index.asp  
\textsuperscript{5} Klasco RK, editor. DRUGDEX® System. Greenwood Village (CO): Thomson MICROMEDEX; 2016.
Regarding medicines most used in acute conditions, important differences are found in the characteristics of the most commonly used drugs in the first two years of life compared to older children. The presence of ascorbic acid, cholecalciferol+retinol, ferrous sulfate and multivitamins among the 10 drugs most used by children under 12 shows that supplementation with vitamins alone or in combination in the first years of life is common practice in pediatrics, despite not always being supported by evidence. Among preschool children, what draws attention is the higher frequency of antimicrobials, including amoxicillin, sulfamethoxazole+trimethoprim, and amoxicillin+clavulanate, among the 10 most cited drugs. These results suggest that with increasing age, the higher incidence of infectious diseases, particularly respiratory, leads to greater use of antimicrobials. The age groups of two to five years and six to 12 years show the use of nimesulide, a drug with risk of liver toxicity and Reye’s syndrome in children with symptoms of viral infection, being contraindicated for children under the age of 12 according to the standard package insert approved by ANVISA.

This study has limitations. It uses information provided by interviewees on the presence of chronic disease, which can lead to overestimation of prevalence of use. On the other hand, socio-cultural aspects involving the use of medicines, particularly when related to risk groups, may contribute to parents (the main respondents in this research) giving socially desirable answers. Thus, omissions in reporting the use of certain medicines cannot be ruled out. Finally, the use of drugs for diseases that are typical in colder months, especially in the South and Southeast Regions, may be underrepresented, given that data collection occurred during spring and summer.

The results of this study indicate that a considerable percentage of Brazilian children make use of medicines, especially to treat acute conditions. Children using drugs for chronic diseases have a different demographic profile compared to those using drugs for acute conditions according to gender, age, and geographic region. Among the most commonly used drugs are medicines acknowledged as effective for pediatric use and others whose effectiveness and safety are uncertain when used in children, particularly those under the age of two.

REFERENCES

1. Barros M. Inquéritos domiciliares de saúde: potencialidades e desafios. Rev Bras Epidemiol. 2008;11 Supl 1:6-19. DOI:10.1590/S1415-790X2008000500002
2. Bertoldi AD, Silveira MP, Menezes AM, Assunção MC, Gonçalves H, Hallal PC. Tracking of medicine use and self-medication from infancy to adolescence: 1993 Pelotas (Brazil) birth cohort study. J Adolesc Health. 2012;51(6 Suppl):S11-5. DOI:10.1016/j.jadohealth.2012.06.027
3. Carnovale C, Conti V, Perrone V, Antoniazzi S, Pozzi M, Merlino L, et al. Paediatric drug use with focus on off-label prescriptions in Lombardy and implications for therapeutic approaches. Eur J Pediatr. 2013;172(2):1679-85. DOI:10.1007/s00431-013-2111-7
4. Carrasco-Garrido P, Jiménez-García R, Barrera VH, Andrés AL, Miguel AG. Medication consumption in the Spanish paediatric population: related factors and time trend, 1993-2003. Br J Clin Pharmacol. 2009;68(3):455-61. DOI:10.1111/j.1365-2125.2009.03449.x
5. Coelho HL, Rey LC, Medeiros MS, Barbosa RA, Cruz Fonseca SG, Costa PQ. Uma comparação crítica entre a Lista de Medicamentos Essenciais para Crianças da Organização Mundial de Saúde e a Relação Nacional de Medicamentos Essenciais (Rename). J Pediatr (Rio J). 2013;89(2):171-8. DOI:10.1016/j.jped.2013.03.004
6. Costa PQ, Rey LC, Coelho HL. Carência de preparações medicamentosas para uso em crianças no Brasil. J Pediatr (Rio J). 2009;85(2):229-35. DOI:10.1590/S0021-75572009000300008
7. Cox ER, Halloran DR, Homan SM, Welliver S, Mager DE. Trends in the prevalence of chronic medication use in children: 2002-2005. Pediatrics. 2008;122(5):e1053-61. DOI:10.1542/peds.2008-0214
8. Cruz MJB, Dourado LFN, Bodevan EC, Andrade RA, Santos DF. Medication use among children 0-14 years old: population baseline study. *J Pediatr (Rio J)*. 2014;90(6):608-15. DOI:10.1016/j.jped.2014.03.004

9. De-Regil LM, Jefferds ME, Sylvetsky AC, Dowswell T. Intermittent iron supplementation for improving nutrition and development in children under 12 years of age. *Cochrane Database Syst Rev*. 2011;(12):CD009085. DOI:10.1002/14651858.CD009085.pub2

10. Eggan AE. Patterns of medicine use in a general population (0-80 years). The Influence of age, gender, diseases and place of residence on drug use in Norway. *Pharmacoepidemiol Drug Saf*. 1997;6(3):179-87. DOI:10.1002/(SICI)1099-1557(199705)6:3<179:AID-PDS258>3.0.CO;2-P

11. Goossens H, Ferech M, Stichele RV, Elseviers M; ESAC Project Group. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. *Lancet*. 2005;365(9459):579-87. DOI:10.1016/S0140-6736(05)17907-0

12. Hämeen-Anttila K, Lindell-Osuagwu L, Sepponen K, Vainio K, Halonen P, Ahonen R. Factors associated with medicine use among children aged under 12 years: a population survey in Finland. *Pharmacoepidemiol Drug Saf*. 2010;19(4):400-407. DOI:10.1002/pds.1887

13. Hoppu K, Anabwani G, Garcia-Bournissen F, Gazarian M, Kearns GL, Nakamura H, et al. The status of paediatric medicines initiatives around the world: what has happened and what has not. *Eur J Clin Pharmacol*. 2012;68(1):1-10. DOI:10.1007/s00228-011-1089-1

14. Imdad A, Herzer K, Mayo-Wilson E, Yakoob MY, Bhutta ZA. Vitamin A supplementation for preventing morbidity and mortality in children from 6 months to 5 years of age. *Cochrane Database Syst Rev*. 2010;(12):CD008524. DOI:10.1002/14651858.CD008524.pub2

15. Knopf H. [Medicine use in children and adolescents. Data collection and first results of the German Health Interview and Examination Survey for Children and Adolescents (KiGGS)]. *Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz*. 2007;50(5-6):863-70. DOI:10.1007/s00103-007-0249-z

16. Knopf H, Wolf IK, Sarganas G, Zhuang W, Rascher W, Neubert A. Off-label medicine use in children and adolescents: results of a population-based study in Germany. *BMC Public Health*. 2013;13:631. DOI:10.1186/1471-2458-13-631

17. Lasky T. Estimates of pediatric medication use in the United States: current abilities and limitations. *Clin Ther*. 2009;31(2):436-45. DOI:10.1016/j.clinthera.2009.02.003

18. Mengue SS, Bertoldi AD, Boing AC, NUL Tavares, da Silva Dal Pizzol T, Oliveira MA, et al. Pesquisa Nacional sobre Acesso, Utilização e Promoção do Uso Racional de Medicamentos (PNAUM): métodos do inquérito domiciliar. *Rev Saude Publica*. 2016;50(supl 2):4s. DOI:10.1590/S1518-8787.2016050006156

19. Moraes CG, Mengue SS, Tavares NUL, Dal Pizzol TS. Utilização de medicamentos entre crianças de zero a seis anos: um estudo de base populacional no sul do Brasil. *Cienc Saude Coletiva*. 2013;18(12):3585-3593. DOI:10.1590/S1413-812320130012000015

20. Oliveira EA, Bertoldi AD, Domingues MR, Santos IS, Barros AJD. Uso de medicamentos do nascimento aos dois anos: Coorte de Nascimentos de Pelotas. *Rev Saude Publica*. 2010;44(4):591-600. DOI:10.1590/S0034-89102011000400002

21. Perrott DA, Piira T, Goodenough B, Champion GD. Efficacy and safety of acetaminophen vs ibuprofen for treating children's pain or fever: a meta-analysis. *Arch Pediatr Adolesc Med*. 2004;158(6):521-6. DOI:10.1001/archpedi.158.6.521

22. Rossi F. The challenges of antimicrobial resistance in Brazil. *Clin Infect Dis* 2011;52(9):1138-43. DOI:10.1093/cid/cir120

23. Santos DB, Barreto ML, Coelho HLL. Utilização de medicamentos e fatores associados entre crianças residentes em áreas pobres. *Rev Saude Publica* 2009;43(5):768-78. DOI:10.1590/S0034-89102009000500005

24. Santos DB, Barreto ML, Coelho HLL. Use of prescribed and non-prescribed medications among children living in poor areas in the city of Salvador, Bahia State, Brazil. *Cad Saude Publica*. 2011;27(10):2032-40. DOI:10.1590/S0102-311X20110000016

25. Vernacchio L, Kelly JP, Kaufman DW, Mitchell AA. Medication use among children <12 years of age in the United States: results from the Slone Survey. *Pediatrics*. 2009;124(2):446-54. DOI:10.1542/peds.2008-2869
26. Winzenberg T, Powell S, Shaw KA, Jones G. Effects of vitamin D supplementation on bone density in healthy children: systematic review and meta-analysis. *BMJ*. 2011;342:c7254. DOI:10.1136/bmj.c7254

**Funding**: Department for Pharmaceutical Services and Strategic Health Supplies (DAF) and Department of Science and Technology (DECIT) of the Secretariat of Science, Technology and Strategic Inputs – SCTIE of the Ministry of Health (Process 25000.111834/2011-31).

**Authors’ Contributions**: design, analysis, interpretation of results, and critical review of intellectual content: TSDP, NULT, SSM. All authors participated in drafting the study, approved the final version of the manuscript and declare they are responsible for all aspects of the work, ensuring its accuracy and integrity.

**Acknowledgments**: Departments of Science and Technology (DECIT) and Pharmaceutical Services (DAF) of the Secretariat of Science, Technology and Strategic Inputs (SCTIE) of the Ministry of Health (MS) for funding and technical support to carry out the National Survey on Access, Use and Promotion of Rational Use of Medicines, and in particular the team that worked on data collection, represented here by Professor Alexandra Crispim Boing and the project’s statistical support team, by Amanda Ramalho Silva, Andréia Fontanella and Luciano Santos Pinto Guimarães.

**Conflict of Interest**: The authors declare no conflict of interest.